Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 110,871

Document Document Title
WO/2018/010441A1
Provided are a series of Chinese medicine healthcare preparations for slimming and weight loss prepared from basic active pharmaceutical ingredients consisting of rose flower, soybean protein isolate, konjac flour, soybean oligosaccharid...  
WO/2018/010965A1
Embodiments of the invention are directed to new equatorially modified polymer linked multimers of guanosine-3', 5'-cyclic monophosphate (cGMP) analogues that inhibit the cGMP-signaling system. The invention is also directed to related m...  
WO/2018/012262A1
[Problem] To provide a metabolic syndrome inhibitor which can inhibit the accumulation of visceral fat and body fat to thereby ameliorate or prevent metabolic syndrome. [Solution] The metabolic syndrome inhibitor according to the present...  
WO/2018/010622A1
Provided are a preparation method for a crystalline form of the compound represented by formula (A), as well as a method for preparation thereof, a composition thereof, and an application thereof in preparing an angiotensin II receptor a...  
WO/2018/010656A1
A pyrrolidine derivative serving as a PPAR agonist, and applications thereof in treating diseases of pathways related to a PPAR receptor, such as nonalcoholic steatohepatitis, complication fibrosis, insulin resistance, primary biliary ch...  
WO/2018/012578A1
The present invention addresses the problem of providing a novel, safe, and side-effect-free ghrelin secretion promotor capable of enhancing the ghrelin secretory function present in the human body, wherein the promotor is provided in th...  
WO/2018/013915A1
Methods of preventing and/or treating reperfusion injury are provided. The methods involve administering alpha-2-macroglobulin (A2MG) to a subject with ischemia in one or more tissues or organs, in order to prevent or decrease reperfusio...  
WO/2018/012634A1
Provided is a prophylactic or therapeutic agent for pulmonary hypertension, said agent comprising a compound represented by formula (I) or a salt thereof. In formula (I): -A- represents -NH-, -S- or -O-; R1 and R2 are the same or differe...  
WO/2018/011265A1
The invention relates to compounds of Formula (I), wherein X, R1A, R1B and R2 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of...  
WO/2018/010332A1
The present invention belongs to the field of pharmaceutical chemical technologies, and in particular relates to the use of 7-hydroxy-butyphthalide in the preparation of drugs for preventing and/or treating cardiovascular and cerebrovasc...  
WO/2018/008021A1
The present invention provides methods and compositions for treating damage to the heart tissue. In particular, the present invention provides pharmaceutical compositions comprising stem cells embedded in biocompatible thermoreversible y...  
WO/2018/009622A1
The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitor...  
WO/2018/006667A1
Disclosed are antihypertensive peptides and antihypertensive proteins and a use thereof. The amino acid sequences of the antihypertensive peptides are respectively TTW, VHW and KAKW, and the amino acid sequences of the antihypertensive p...  
WO/2018/009732A1
The present invention provides anti-Activin A antibodies, and antigen-binding fragments thereof, as well as methods of use of such antibodies, or antigen-binding fragments thereof, for treating a subject having pulmonary arterial hyperte...  
WO/2018/008729A1
The present invention addresses the problem of providing a therapeutic agent for ischemic diseases, which exhibits a tissue-protecting effect against tissue injuries associated with ischemia. The therapeutic agent according to the presen...  
WO/2018/009602A2
The present disclosure relates to novel processes for the preparation of compounds useful as stimulators of soluble guanylate cyclase (sGC). These processes are amenable to large scale preparation and produce stable 3-(2-pyrimidinyl)pyra...  
WO/2018/007820A1
The present invention relates to compositions comprising one or more probiotic bacterial strains and one or more lipid modifing active ingredients. The compositions can be used in the management of cholesterol and/or hypertension.  
WO/2018/009627A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/008219A1
The present invention provides: a method for producing an amidoxime compound, wherein a nitrile compound and hydroxylamine and/or an acid salt of hydroxylamine are reacted with each other in a reaction solvent that contains an alcohol ha...  
WO/2018/009625A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/009875A1
Methods and compositions for use in treating atrial fibrillation in a subject. The compounds of the present invention are gamma-ketoaldehyde scavengers.  
WO/2018/000047A1
The present invention relates to the use of substituted quinoline compounds for treating immunoglobulin light chain (LC) amyloidosis (AL), especially cardiotoxicity associated with immunoglobulin LC AL. In particular, the substituted qui...  
WO/2018/002215A1
The present invention relates to methods and pharmaceutical compositions for the treatment of cardiomyopathies. The inventors showed that the nicotinamide riboside kinase Nmrk2 gene involved in NAD+ biosynthetic pathway is strongly induc...  
WO/2018/003857A1
Provided is a curcumine preparation which is highly water soluble, is capable of maintaining a sufficiently high blood concentration of free curcumine and capable of effectively obtaining the pharmacological effect of curcumine by parent...  
WO/2018/003983A1
The invention provides a drug and a method for producing same, said drug having as an active ingredient a conjugate, in which an hANP peptide is bound to a sugar chain (N297 sugar chain) that binds to Asn 297 of an Fc-containing molecule...  
WO/2018/005356A1
Compounds within the scope of the present invention have a Formula 1 or a salt or produg thereof, where ring A is selected from cycloaliphatic; ring B is aryl; R1 is selected from (C1-C10)alkyl, (C3-C10)cycloalkyl, halo, aryl, and hetero...  
WO/2018/002124A1
The present invention relates to a novel two -component composition comprising acetylsalicylic acid (ASA) and which is particularly useful in providing an aqueous solution of ASA for immediate peroral administration.  
WO/2018/002873A1
The present invention relates to the use of 0-(3-piperidino-2-hydroxy-l-propyl)- nicotinic amidoxime (BGP15), its tautomers, enantiomers and pharmaceutically acceptable salts thereof the treatment of diseases characterised at least in pa...  
WO/2018/005591A1
The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of ...  
WO/2018/003997A1
The present invention addresses the problem of providing a safe and easy-to-prepare cell preparation for prevention and/or treatment of organ fibrosis such as liver fibrosis. Provided is a cell preparation for prevention and/or treatment...  
WO/2018/005177A1
The present invention relates to compounds of formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these co...  
WO/2018/003569A1
Provided is a method for producing an unsaturated fatty acid oxide (e.g. ω3 fatty acid oxide) that is new and has more beneficial features compared to conventional technologies. This method uses a lipoxygenase-containing composition (e....  
WO/2018/005336A1
The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or e...  
WO/2017/221845A1
The invention provides a blood flow-improving agent including as an active ingredient 10-hydroxydecanoic acid.  
WO/2017/222042A1
The application provides an ophthalmic pharmaceutical composition containing a compound of formula (I) or an ester, oxide, prodrug, or pharmaceutically acceptable salt or solvate thereof contained in a high-density lipoprotein. In formul...  
WO/2017/219453A1
Provided in the present invention is a valsartan dispersible tablet consisting of a valsartan, hydroxypropyl-β-cyclodextrin, a pharmaceutically acceptable excipient, a binder, glidant, flavoring agent and Semen Cassiae, wherein: the pha...  
WO/2017/221012A1
The present invention relates to a new use of compounds that are angiotensin II (Ang II) agonists, more particularly agonists of the Ang II type 2 receptor (the AT2 receptor), and especially agonists that bind selectively to the AT2 rece...  
WO/2017/219689A1
The present invention relates to a hydrochloride for inhibiting a PIM kinase, and a manufacturing method and application of the hydrochloride. The structure of the hydrochloride for inhibiting the PIM kinase is represented by formula (II...  
WO/2017/219688A1
The present invention relates to a pyrimidine compound, a chloride salt thereof, and a manufacturing and application of same. The chloride salt of the pyrimidine compound is represented by formula (II). The chloride salt has higher solub...  
WO/2017/219500A1
Provided is a pyrimidine compound as shown in formula I, a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The pyrimidine compound can inhibit the activation or resistant mutation of one or more EGFRs, c...  
WO/2017/220544A1
The invention relates to a compound of formula (I) wherein R wherein R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2017/220516A1
The invention relates to a compound of formula (I) containing at least one diazirenyl. The compound of formula (I) is a type-2 cannabinoid (CB2) receptor modulator and can be used as a medicament.  
WO/2017/220369A1
The present invention provides an isolated monoclonal antibody or an antigen portion thereof which: a) binds to Mac-1, b) specifically inhibits the interaction of CD40L with activated Mac-1 and c) does not induce integrin outside-in sign...  
WO/2017/220042A2
Disclosed are an amrinone pharmaceutical composition and an application thereof in hypertension treatment. The amrinone pharmaceutical composition contains amrinone and a natural product compound (I) separated from dried blackberry lily ...  
WO/2017/220845A1
The invention relates to compositions used to relieve, improve, prevent and/or treat stretch marks and/or skin ulcers preferably of ischemic origin. The invention also relates to the composition, pharmaceutical form and uses thereof.  
WO/2017/222029A1
The present invention provides fermented milk having a high angiotensin converting enzyme inhibition activity, a high hypotensive activity and/or a high stroke-preventing activity. The present invention also provides a method for produci...  
WO/2017/221883A1
[Problem] The present invention provides an antibody-drug conjugate (ADC). The present invention also provides a conjugate of an anti-CD71 antibody or an antigen-binding fragment thereof with a drug. The present invention further provide...  
WO/2017/218576A1
Carvedilol parenteral sustained release systems by IV infusion, injection, or subcutaneous routes are disclosed. Preparation of carvedilol disperse systems such as liposomes, biodegradable microparticles or nanparticles, and polymeric mi...  
WO/2017/215589A1
A halogenated compound, an axially chiral isomer thereof, and an application thereof in preparing drugs for disorders closely related to aberrant levels of uric acid.  
WO/2017/216563A1
The invention relates to the use of a poly(ADP ribose) polymerase (PARP) inhibitor and/or a tetracycline, for treating, preventing or ameliorating medial vascular calcification or intimal atherosclerotic calcification, and to pharmaceuti...  

Matches 1 - 50 out of 110,871